PHARMACOKINETICS OF 4-[4''-(2'',2'',6'',6''-TETRAMETHYL-1'' IPERIDINYLOXY)AMINO]-4'-DEMETHYLEPIPEDOPHYLLOTOXIN IN MICE BEARING SARCOMA-180

''-(2'',2'',6'',6''-tetramethyl-1''-piperindyloxy) amino ]-4'-demethyl epipodophyllotoxin ( GP-7) in mice bearing sarcoma 180. METHOD: Using HPLC with a uv detector at 285 nm. RESULTS: The plasma concentration-t ime course of GP-7 in mice was best fitted to a 2-compartment open mod le after iv 20, 60 mg . kg(-1). At both doses the plasma T1/2 beta was around 40 min. The highest concentration was found in liver and lung. The level of GP-7 was higher in tumor than in kidney, spleen, and bon e marrow after ip 20 mg . kg(-1) for 10 d. Urinary excretion of GP-7 a s unchanged drug accounted for about 20 % of the administered doses 72 h after injection. CONCLUSION: GP-7 disappeared more slowly from the plasma of mice bearing sarcoma 180, distributed extensively over the t issues and was partially excreted from urine. The concentrition of GP- 7 in tumor was higher.